Top

Insulin Market in Europe 2015-2019

Category : Pharmaceuticals  | Published Date : Jul-2015 | Pages : 80
enquire GET DISCOUNT
About insulin
Insulin is a hormone produced by the beta cells of the pancreas; insulin has a key role in regulating the blood glucose levels. It regulates the metabolism of glucose and other nutrients in the body. Insulin permits the body to utilize sugar (glucose) from carbohydrates in the food for energy or to store glucose for future use. The beta cells of the pancreas of people with type 1 diabetes do not produce sufficient insulin to regulate blood glucose level; therefore, they need to intake insulin daily. On the other hand, people with type 2 diabetes or gestational diabetes need doses of insulin together with other medication. Different type of insulin such as human insulin and insulin analogs are available for insulin replacement therapy.

Technavio's analysts forecast the insulin market in Europe to grow at a CAGR of 6.50% over the period 2014-2019.

Covered in this report
The report covers the present scenario and the growth prospects of the insulin market in Europe for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various insulin used for the treatment of diabetes.

Technavio's report, Insulin Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the insulin market in Europe and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key vendors
• Elli Lilly  
• Novo Nordisk 
• Sanofi

Other prominent vendors
• Biodel 
• Boehringer Ingelheim 
• Bristol-Myers Squibb
• Diamyd Medical 
• DiaVacs 
• Generex Biotechnology 
• Lexicon Pharmaceuticals 
• Macrogenics 
• Merck
• Osiris Therapeutics 
• Pfizer
• Tolerion
• XOMA 

Key market driver
• Increase in prevalence of diabetes
• For a full, detailed list, view our report

Key market challenge
• Stringent regulatory environment
• For a full, detailed list, view our report

Key market trend
• Rise in awareness programs
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1 Humalog
04.2 Liprolog
04.3 Actrapid
04.4 Levemir
04.5 NovoMix
04.6 NovoRapid
04.7 Tresiba
04.8 Apidra
04.9 Insuman
04.10 Lantus
04.11 Toujeo
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Insulin: An Overview
07.1 Product Portfolio
07.2 Epidemiology
07.3 Pipeline Portfolio
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Type
09.1 Fast-acting Insulin
09.1.1 Rapid-acting Insulin
09.1.2 Regular Human Insulin
09.2 Intermediate-acting Insulin
09.2.1 NPH Human Insulin
09.2.2 Pre-mixed Insulin
09.3 Long-acting Insulin
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and Their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and Their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.2.1 Novo Nordisk
17.2.2 Sanofi
17.2.3 Eli Lilly
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Eli Lilly
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation by Revenue
18.1.4 Sales by Geography
18.1.5 Business Strategy
18.1.6 Key Information
18.1.7 SWOT Analysis
18.2 Novo Nordisk
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation by Revenue 2013
18.2.4 Business Segmentation by Revenue 2012 and 2013
18.2.5 Sales by Geography
18.2.6 Business Strategy
18.2.7 Key Information
18.2.8 SWOT Analysis
18.2.9 Strengths
18.2.10 Weakness
18.2.11 Opportunities
18.2.12 Threats
18.3 Sanofi
18.3.1 Key Facts
18.3.2 Business Description
18.3.3 Business Segmentation
18.3.4 Revenue by Business Segmentation
18.3.5 Revenue Comparison 2012 and 2013
18.3.6 Sales by Geography
18.3.7 Business Strategy
18.3.8 Key Developments
18.3.9 SWOT Analysis
19. Other Reports in This Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Number of People Aged 20-79 with Diabetes in Europe 2013 and 2035 (millions)
Exhibit 3: Percentage of People Aged 20-79 with Diabetes in Europe 2013 and 2035
Exhibit 4: Percentage of Undiagnosed People Aged 20-79 with Diabetes in Europe by Income 2013
Exhibit 5: Top Four Countries in Europe with High Proportion of Diabetic People 2013 (millions)
Exhibit 6: Few Countries in Europe with High Proportion of Diabetic People Aged 20-79 by Gender 2014
Exhibit 7: Insulin Market in Europe 2014-2019 ($ millions)
Exhibit 8: Segmentation of Insulin Market in Europe by Type
Exhibit 9: Major Drivers of Insulin Market in Europe
Exhibit 10: Percentage of People with Diabetes in 28 Member Countries in EU by Age Group 2013-2040
Exhibit 11: Percentage of People with Diabetes in Few European Countries by Age Group 2014
Exhibit 12: Factors Influencing Development of Insulin Delivery Devices
Exhibit 13: Diabetes Rule of Halves
Exhibit 14: Number of Diabetes and Undiagnosed Diabetes Cases in Few European Countries Among People Aged 20-79 2014
Exhibit 15: Ranking of Top Vendors
Exhibit 16: Novo Nordisk: Revenue of Insulin Products in Europe 2011-2014 ($ millions)
Exhibit 17: Novo Nordisk: YoY Growth and Revenue of NovoRapid in Europe 2011-2014 ($ millions)
Exhibit 18: Novo Nordisk: YoY Growth and Revenue of NovoMix in Europe 2011-2014 ($ millions)
Exhibit 19: Novo Nordisk: YoY Growth and Revenue of Levemir in Europe 2011-2014 ($ millions)
Exhibit 20: Novo Nordisk: YoY Growth and Revenue of Human Insulins in Europe 2011-2014 ($ millions)
Exhibit 21: Sanofi: YoY Growth and Revenue of Lantus in Western Europe 2011-2014 ($ millions)
Exhibit 22: Sanofi: YoY Growth and Revenue of Apidra in Western Europe 2011-2014 ($ millions)
Exhibit 23: Sanofi: YoY Growth and Revenue of Insuman in Western Europe 2011-2014 ($ millions)
Exhibit 24: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 25: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 26: Eli Lilly: Sales by Geography 2013
Exhibit 27: Novo Nordisk: Business Segmentation by Revenue 2013
Exhibit 28: Novo Nordisk: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 29: Novo Nordisk: Sales by Geography 2013
Exhibit 30: Sanofi: Business Segmentation
Exhibit 31: Sanofi: Revenue by Business Segmentation 2013
Exhibit 32: Sanofi: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 33: Sanofi: Sales Revenue by Geographical Segmentation 2013
...
Publisher Name : Technavio

SIMILAR MARKET STUDIES

Please Select Format
Single User: US $ 2500
Five User: US $ 3000
Site User: US $ 4000
Global User: US $ 10000

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top